Novartis partners with Asieris to bet on cardiovascular asset, with a total transaction amount of up to 5.2 billion USD
I'm PortAI, I can summarize articles.
Swiss pharmaceutical giant Novartis has reached a collaboration with Chinese biotechnology company Asieris, signing a multi-asset licensing and option agreement with a total transaction value of up to $5.2 billion. Novartis will obtain the rights to develop and commercialize two drugs and will have the right of first negotiation after Asieris completes clinical trials. Asieris will receive a $160 million upfront payment and subsequent milestone payments, with future opportunities for sales sharing and equity financing support
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments